NovoCure price to book ratio NVCR

Market value divided by the book value of the company's net assets, since 2015.

Today, Oct 23, 2026: 5.1×
10-year median: 16.7×
Against its 10-year history: 21st; percentile: 0 is its lowest day, 100 its highest
10-year range: 2.8× to 63.1×
Peer median: 4.8×

NovoCure's price to book ratio is 5.1× as of Oct 23, 2026.

That is below its ten-year median of 16.7×, lower than on 79% of days in the last ten years.

Over that time it ranged from 2.8× in Oct 2016 to 63.1× in Feb 2021.

The median for 10 medical instruments and supplies stocks of a similar size is 4.8×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	5.1×	3.3×	6.3×
2025	4.4×	3.6×	9.1×
2024	9.2×	3.6×	10.0×
2023	4.1×	3.0×	25.7×
2022	17.3×	13.9×	22.3×
2021	18.9×	18.9×	63.1×
2020	57.4×	24.5×	57.4×
2019	45.5×	27.2×	57.9×
2018	26.6×	15.3×	43.4×
2017	15.5×	3.4×	16.7×
2016	4.3×	2.8×	13.9×
2015	15.4×	15.2×	19.1×

Against its peers

Companies in Medical - Instruments & Supplies nearest NovoCure's size, closest first, today.

Company	Price to book ratio
NVCRNovoCure	5.1×
LMATLemaitre Vascular	4.6×
EYENational Vision	1.6×
INSPInspire Medical Systems	2.5×
CDRECadre	3.7×
UFPTUFP Technologies	5.0×
BVSBioventus	5.5×
STAAStaar Surgical	3.1×
IRMDIradimed	10.8×
ATRCAtriCure	5.8×
WRBYWarby Parker	8.2×
Peer median	4.8×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on NovoCure

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.